Dr. Claire de la Calle

And then there's misclassification issues, like we discussed, such as discrepancies between pathology reads and radiology reads.

If we could have a simple liquid biomarker, just one number that does all of that in one number, that would be the holy grail, I think, for active surveillance patients.

My message is

For the really low volume, pattern 4, so gray group 2 patients with low tumor volume, low PSA density, non-concerning PSA candidate, relatively stable MRI, or non-concerning MRI, I think active surveillance really should be considered in those patients.

We didn't really talk about this, but there are some really great genomic studies out there that show that that subset of gray group 2 patients at the genomic level is essentially the same as low-risk patients.

And so that kind of biologically confirms what the studies we mentioned earlier show, that those patients have the same outcomes.

And so I think we really need to get that message out there that there are some intermediate risk patients that are great candidates for active surveillance.

The questions really are around the patients with more pattern 4, consistently rising PSA, high obesity, concerning MRI findings, concerning genomics.

We really need to do more research in that space.

And in that space, if the patient's very anxious, if the provider's anxious, I don't think we should fault anyone for seeking treatment, active treatment in that setting.

So I think at least we have clear indications for surveillance in the really low-risk areas.

Grade group two patients.

Yeah.

And in everyone else than we, we still need to do some research.

Jose Silva.

Our audio team is led by Kieran Gannon with support from Aaron Bowles, Gabe DeGrezio, and Josh Spencer.

Design and digital marketing led by Brian Schmitz.

Social media and PR by Chi Dang.

Administrative support provided by Judy De La Cruz.

Thanks again for listening and see you next week.